glp-1 adoption Impact: How GLP-1s Are Changing the Diabetes Treatment Paradigm research2guidance - GLP-1 Market: The

Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes

[57] demonstrated that GLP-1 based agents were associated with a three-fold increased risk of pancreatic enzyme elevation relative to controls, yet did not indicate a significant rise in pancreatitis or pancreatic cancer

The best comparison runs across three dimensions: mechanism, published trial efficacy, and reported tolerability

Additionally, there were more deaths in the Tirzepatide group than semaglutide (12 vs 1)

Ricks is hopeful that more insurers will come around as the drugs show their long-term value in reducing not only obesity but its associated conditions like heart disease